Every 424B that Global Medical REIT Inc. (GMRE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow GMRE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GMRE filings page.
Chiron Real Estate Inc. intends to offer up to $75,000,000 of 8.00% Series B Cumulative Redeemable Preferred Stock in an at-the-market offering under a Sales Agreement dated March 12, 2026.
The offering may be sold through agents or directly to agents as principals, with agents entitled to up to 2.0% of gross proceeds. Net proceeds are intended to be contributed to the Operating Partnership in exchange for Series B Preferred OP Units and used for general corporate purposes, which may include funding acquisitions and repaying borrowings under the Credit Facility.
Chiron Real Estate Inc. is registering up to $288,010,090 of common stock offered under an amended at-the-market sales agreement dated March 12, 2026, reflecting $11,989,910 previously sold under the program and an original program capacity of $300,000,000.
The supplement permits sales through multiple Agents and forward sale arrangements with specified Forward Purchasers and Forward Sellers, and describes settlement options (physical, cash or net share) and related underwriting-style compensation (up to 2.0%). Proceeds contributed to the Operating Partnership may repay Credit Facility borrowings, fund acquisitions or be used for general corporate purposes.
Global Medical REIT Inc. (GMRE) launched a primary offering of 2,000,000 shares of its 8.00% Series B Cumulative Redeemable Preferred Stock at $25.00 per share. The underwriting discount is $0.7875 per share, for gross proceeds of $50,000,000 and proceeds before expenses of $48,425,000. The company estimates net proceeds of approximately $48.1 million, or approximately $55.4 million if the 300,000‑share over‑allotment option is exercised in full.
Dividends accrue at 8.00% of the $25.00 liquidation preference ($2.00 per share annually), payable quarterly, with the first, a pro rata $0.388 per share, scheduled for January 31, 2026 to holders of record on January 15, 2026. The shares are perpetual, callable at the company’s option on or after November 20, 2030 at $25.00 plus accrued and unpaid dividends, and feature a Change of Control conversion right and special optional redemption.
GMRE intends to apply to list the Series B on the NYSE as “GMRE PrB.” Net proceeds will be contributed to the Operating Partnership for general corporate purposes, including funding acquisitions and repaying indebtedness under the Credit Facility.
Global Medical REIT Inc. (GMRE) launched a primary offering of Series B Cumulative Redeemable Preferred Stock. The shares carry a $25.00 per share liquidation preference, pay cumulative cash dividends quarterly in arrears on January 31, April 30, July 31 and October 31, commencing on January 31, 2026 to holders of record as of January 15, 2026. The stock is perpetual, with optional redemption on or after 2030 at $25.00 plus accrued and unpaid dividends.
Upon a Change of Control, holders may convert into GMRE common stock (subject to a share cap and alternative consideration mechanics), unless the shares are called for redemption. Voting rights are limited to protective provisions and the right to elect two directors if six or more quarterly dividends are in arrears. GMRE’s charter includes a 9.8% ownership limit per class or series to support REIT qualification.
GMRE intends to apply to list the new preferred on the NYSE as “GMRE PrB”, with trading expected within 30 days after initial delivery. Net proceeds will be contributed to the operating partnership for general corporate purposes, including acquisitions and repaying indebtedness under the Credit Facility.